Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Balixafortide by Spexis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Balixafortide is under clinical development by Spexis and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Data Insights
Murepavadin by Spexis for Bronchiectasis: Likelihood of Approval
Murepavadin is under clinical development by Spexis and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs...